Journal
ONCOGENE
Volume 27, Issue 26, Pages 3739-3745Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1211042
Keywords
ABIN; NF-kappa B; ubiquitin; TNF; protein-protein interaction
Funding
- NATIONAL CANCER INSTITUTE [ZIABC010779, Z01BC010779] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Deregulated nuclear factor kappa B (NF-kappa B) activation plays an important role in inflammation and tumorigenesis. ABIN proteins have been characterized as negative regulators of NF-kappa B signaling. However, their mechanism of NF-kappa B inhibition remained unclear. With the help of a yeast two-hybrid screen, we identified ABIN proteins as novel ubiquitin-interacting proteins. The minimal ubiquitin-binding domain (UBD) corresponds to the ABIN homology domain 2 (AHD2) and is highly conserved in ABIN-1, ABIN-2 and ABIN-3. Moreover, this region is also present in NF-kappa B essential modulator/I kappa B kinase gamma (NEMO/IKK gamma) and the NEMO-like protein optineurin, and is therefore termed UBD in ABIN proteins and NEMO (UBAN). Nuclear magnetic resonance studies of the UBAN domain identify it as a novel type of UBD, with the binding surface on ubiquitin being significantly different from the binding surface of other UBDs. ABIN-1 specifically binds ubiquitinated NEMO via a bipartite interaction involving its UBAN and NEMO-binding domain. Mutations in the UBAN domain led to a loss of ubiquitin binding and impaired the NF-kappa B inhibitory potential of ABINs. Taken together, these data illustrate an important role for ubiquitin binding in the negative regulation of NF-kappa B signaling by ABINs and identify UBAN as a novel UBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available